Bradley Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
Completes acquisition of approximately 68% of OTC manufacturer Doak Pharmacal for approximately $950,000 paid to Doak Chairman John Krafchuk and President Lorna Adams. A merger agreement for the remainder of Doak was approved by the existing board based upon the total purchase price of $1.4 mil. and will be considered by the new board, which will be named shortly. Also under the deal, Bradley Chairman and CEO Daniel Glassman will become chairman and president of Doak. Bradley announced the deal in October 1993 ("The Tan Sheet" Nov. 1, 1993, p. 7)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning